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Recent studies indicate that cancer antigen 125 (CA125) response criteria tend to overestimate a tumour reduction measured by
standard WHO response criteria in recurrent epithelial ovarian carcinoma. The aim of the study was to validate the recently
introduced GCIG (The Gynaecological Cancer Intergroup) CA125 response criteria in predicting a tumour response measured by
WHO (World Health Organization) criteria. Changes in CA125 levels (GCIG criteria) were retrospectively compared with
alterations in the tumour load (WHO criteria) during second-line chemotherapy with topotecan or paclitaxel–platinum in 124
consecutive patients with recurrent or refractory disease. In patients assessable by both response criteria (n¼72), the overall
response rate using GCIG CA125 criteria was 57% (95% confidence interval (CI): 45–69%) and significantly higher than the response
rate of 39% (95% CI: 28–51%) using WHO response criteria (P¼0.045). The GCIG CA125 criteria had a sensitivity of 96% (95% CI:
82–100%), a specificity of 68% (95% CI: 52–81%) and an accuracy of 79% (95% CI: 68–88%) in predicting a response measured by
WHO criteria. In conclusion, the GCIG CA125 response criteria seem to overestimate a tumour response by WHO criteria when
monitoring the efficacy of second-line chemotherapy with topotecan or paclitaxel–platinum in patients with epithelial ovarian
carcinoma.
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Recurrent epithelial ovarian carcinoma is generally considered as
an incurable disease and second-line chemotherapy may be
administered for palliation of symptoms and extension of survival
(Ozols, 1997; Adams et al, 1998). Response assessment in recurrent
disease is an elusive matter. Many patients presenting with, for
example, peritoneal carcinosis and ill-defined tumours cannot be
adequately monitored with physical examination and conventional
imaging techniques such as computed tomography or ultrasound
scans. The biochemical tumour marker cancer antigen 125
(CA125) is a glycoprotein expressed on the cell surface of epithelial
ovarian cancer cells. Cancer antigen 125 levels are elevated
(X35Uml
 1) in 82% of newly diagnosed ovarian carcinoma
patients and in 74% of patients, the CA125 level is above 65Uml
 1
(Bast et al, 1983; Tuxen et al, 1995). In first-line treatment, serial
changes in CA125 concentrations are well correlated with response
and survival (Rustin et al, 1999). The measurement of CA125 has
as such an established role in the monitoring of the efficacy of
first-line chemotherapy in both clinical trials and in the individual
patient (Berek et al, 1999; Meyer and Rustin, 2000).
In contrast, the clinical use of CA125 in monitoring second-line
treatment is still controversial (Pearl et al, 1994; Davelaar et al,
1996; Bridgewater et al, 1999). Several studies identify patients in
whom the effects of second-line chemotherapy on the CA125 level
are in discordance with the radiographic evaluation of changes in
the tumour load (Eisenhauer et al, 1994; Morgan et al, 1995;
Davelaar et al, 1996). In a recent meta-analysis of 19 phase II trials
including 14 different antineoplastic agents and different first-line
regimens, it was found that CA125 response criteria tend to
overestimate a tumour reduction when compared to WHO (World
Health Organization) tumour response criteria (Rustin et al, 2000).
However, a routine application of a correction factor between the
CA125 and the WHO response rates was not recommended.
The primary aim of the study was to validate the recently
introduced GCIG (The Gynaecological Cancer Intergroup) simpli-
fied CA125 response criteria (Rustin, 2003) in predicting a
response by WHO criteria, in the monitoring of second-line
chemotherapy in a well-defined group of consecutive patients with
epithelial ovarian carcinoma all pretreated with paclitaxel–
platinum as first-line chemotherapy. The second aim was to
evaluate whether the application of an alternative CA125 ratio
response algorithm could increase the accuracy in the prediction
of a tumour response.
MATERIAL AND METHODS
Patients
Since 1994, when paclitaxel–platinum was introduced as standard
first-line chemotherapy for epithelial ovarian carcinoma at the
Finsen Center, all patients with ovarian tumours have been
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lconsecutively registered. The clinical data from patients with
recurrent epithelial ovarian carcinoma have been included in a
clinical database (CODOVA: Copenhagen Database for Ovarian
Carcinoma; The Danish Data Protection Agency No. 2000-41-0126)
(Gronlund et al, 2001; Gronlund et al, 2002a,b). In the period
August 1994 to January 2001, 487 consecutive patients with
primary epithelial ovarian cancer received first-line chemotherapy
with paclitaxel–platinum. Of these, 124 patients received standar-
dised second-line chemotherapy consisting of topotecan (n¼64)
or paclitaxel–carboplatin (n¼60) because of refractory, persistent
or recurrent disease and these patients constitute the study group.
The patient age at the start of second-line chemotherapy was
median 59.4 years (range 34.8–77.2 years). A median number of
six second-line cycles (range 1–16 cycles) were applied as salvage
treatment. The efficacy of the second-line chemotherapy was
routinely assessed by imaging techniques (abdominal and
endovaginal ultrasonography or CT scans) after every two courses
of chemotherapy. Ultrasonographies were performed by senior
consultants at the Department of Radiology, Rigshospitalet. The
duration of treatment was dependent on evaluation of response
and followed departmental guidelines for standard second-line
therapy. In patients obtaining a complete response (CR),
chemotherapy was continued for two cycles after a CR was
obtained. In patients with a partial response (PR) or stable disease
(SD), standard antineoplastic therapy was continued until tumour
progression. Patients with tumour progression or unacceptable
toxicity were offered various regimens such as inclusion in phase II
protocols with investigational drugs, endocrine therapy, or they
received exclusively supportive care. The duration of third- or
fourth-line treatment was similar as for the second-line treatment.
The patient data were retrospectively evaluated with special
focus on response to second-line antineoplastic treatment.
WHO response assessment
The tumour burden was evaluated before the start of second-line
chemotherapy (cycle 1) and, thereafter by every second cycle of
chemotherapy, that is, in relation to cycles 3, 5, 7, etc. All patients
were retrospectively assigned a best response to treatment, that is,
CR4PR4SD4progressive disease (PD) using standard WHO
criteria (Miller et al, 1981). Briefly, a response has occurred if there
has been a reduction of at least 50% in the product of the
diameters of all measurable lesions determined by two observa-
tions not less than 4 weeks apart. Patients having bidimensional
disease assessed by ultrasonography (420mm) or by CT scan
(410mm) were defined as having measurable disease. Nonmea-
surable (NM) disease was defined as lesions measuring less than
20mm by ultrasonography or less than 10mm by CT scan. To
obtain a response by WHO criteria, the patients were thus
requested to have at least two cycles of second-line chemotherapy
followed by evaluation after another 3 weeks, thus precluding
patients who succumbed to disease before 6 weeks after the start of
second-line treatment. These patients were categorised as having
NM disease in this analysis.
CA125 assay
All patients had blood samples taken routinely before the start of
second-line treatment and then prior to each cycle of chemother-
apy. Serum levels of CA125 were determined using an enzyme
immunoassay (Abbott CA125 EIA, Abbott Laboratories, Chicago,
IL, USA) according to the manufacturer’s instruction. The within-
assay coefficient of variation (CV) was 6.6% (n¼60), whereas the
between-assay CV was 6.2% (n¼10) at a control sample of
30Uml
 1. Cancer antigen 125 levels below 35Uml
 1 were
considered as normal in agreement with the literature (Bast et al,
1983; Kenemans et al, 1993; Markman, 1994), and were regardless
of the exact CA125 result changed to o35Uml
 1.
CA125 response algorithms
Two different CA125 response algorithms were applied (1) the
GCIG CA125 response criteria and (2) the CA125 ratio criteria
(Table 1).
GCIG CA125 criteria On the day of the WHO response allocation,
the level of the tumour marker CA125 was compared to the
pretreatment level and a CA125 response was calculated according
to the CA125 response criteria proposed by the GCIG (Rustin,
2003). Briefly, two pretreatment samples at least twice
(X70Uml
 1) the upper cut-off of normal (435Uml
 1) and at
least two additional samples after the start of treatment are
required to have evaluable disease. A response has occurred if
there is at least a 50% decrease that is confirmed by the fourth
sample.
CA125 ratio criteria A CA125 ratio was calculated after every
series of second-line chemotherapy by dividing the actual CA125
level following treatment, by the pretreatment CA125 value directly
prior to the start of second-line treatment, that is, the CA125 ratio
after one cycle means the CA125 ratio after one cycle of
chemotherapy, and this blood sample was obtained approximately
3 weeks after the first cycle just before the administration of the
second cycle (Table 1). Three response categories are defined as
proposed by Davelaar et al (1996).
Response (CRþPR): ratio p0.5.
SD: ratio 40.5 and o2.0.
PD: ratio X2.0.
Patients with an elevated CA125 level over or equal to 70Uml
 1
before the start of second-line treatment were defined as having
evaluable disease. Nonevaluable disease was defined as a CA125
level X35Uml
 1 and o70Uml
 1. To be evaluable by the ratio
criteria, only two samples were required. Whereas the GCIG
criteria are based on alterations in the numeric values of CA125,
the ratio criteria include a time factor, thus reflecting the rate of
decline in CA125 levels. Furthermore, the CA125 ratio does not
necessarily reflect the CA125 level at the day of the WHO best
response allocation.
Statistical methods
In patients assessable both by WHO criteria (measurable disease)
and by CA125 criteria (evaluable disease), the relationship between
a CA125 and a WHO response was expressed by means of the
following definitions. Concordance means that the designations of
response or nonresponse following second-line treatment were
similar using CA125 and WHO tumour response criteria. The
sensitivity of the CA125 criteria to depict a WHO response was
defined as the number of patients with a concordant response in
relation to the total number of patients with a WHO response. The
specificity of the CA125 criteria was defined as the number of
concordant nonresponders in relation to the total number of
nonresponders by the WHO criteria. The positive predictive value
Table 1 Differences between the GCIG CA125 criteria and the CA125
ratio criteria used in the comparison with the WHO response criteria
GCIG criteria Ratio criteria
Pretreatment samples required (n)2 1
Moment of response evaluation Variable
a Fixed
b
Confirmation sample required +  
GCIG¼The Gynaecological Cancer Intergroup; CA125¼cancer antigen 125;
WHO¼World Health Organization.
aDependent on the time of best response
allocation by the WHO response criteria.
bAfter 1, 2, 3,y,M cycles of second-line
chemotherapy.
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l(PPV) of the CA125 criteria was defined as the number of
concordant responders in relation to the total number of patients
with a CA125 response. The negative predictive value (NPV) was
defined as the number of concordant nonresponders in relation
the total number of nonresponding patients by the CA125 criteria.
The accuracy of the CA125 criteria was defined as the number of
patients with concordant response designations in relation to the
total number of patients. The sensitivity, specificity, PPV, NPV and
accuracy in predicting a WHO response were calculated for (A) the
GCIG CA125 response criteria and (B) the different CA125 ratio
response criteria (after 1, 2, 3 and 4 cycles of chemotherapy). The
differences in the ability of the various CA125 response algorithms
to detect a tumour response by WHO criteria were tested with
Fisher’s test. Po0.05 was considered statistically significant.
RESULTS
Tumour response: WHO criteria
Out of 124 patients, 24 had NM disease for assessment by WHO
criteria leaving 100 patients eligible for WHO tumour response
evaluation. The frequencies of CR and PR were 27% (95%
confidence interval (CI): 18–37%) and 14% (95% CI: 8–22%),
respectively. The frequencies of SD and PD were 41% (95% CI:
31–51%) and 18% (95% CI: 11–27%), respectively.
CA125 response: GCIG criteria
Nonevaluable disease was noted in 23 patients with (A) pretreat-
ment levels X35Uml
 1 and o70Uml
 1 (n¼8) or (B) only one
pretreatment sample (470Uml
 1)( n¼9), or (C) two pretreat-
ment samples (470Uml
 1) and less than four total samples
(n¼1), or (D) a combination of these categories (n¼5). In the
nine patients with only one pretreatment sample, seven patients
had a subsequent reduction of more than 75% of the pretreatment
CA125 level. Another 14 patients had CA125 levels below the cut-
off limit of 35Uml
 1, and they were described as CA125 normal.
Hence, 87 patients were eligible for response assessment. The
frequencies of CR and PR were 41% (95% CI: 31–52%) and 16%
(95% CI: 9–26%), respectively. The frequencies of SD and PD were
31% (95% CI: 22–42%) and 11% (95% CI: 6–20%), respectively.
Comparison of WHO and GCIG CA125 criteria
Table 2 shows the relationship between WHO criteria and the
GCIG CA125 criteria in the monitoring of second-line therapy of
epithelial ovarian carcinoma (n¼124). Of 124 patients, 72 were
assessable both by WHO criteria (measurable disease) and by
CA125 criteria (evaluable disease). In these patients (n¼72), the
overall response rate using GCIG CA125 criteria was 57% (95% CI:
45–69%) (41/72) and significantly higher compared to the
response rate of 39% (95% CI: 28–51%) (28/72) using WHO
response criteria (P¼0.045). Hence, either the GCIG CA125
criteria overestimate the WHO response rate by a factor 1.46 or,
alternatively, WHO response criteria underestimate a GCIG CA125
response by a factor 0.68. In an intent-to-treat analysis adding
patients with two elevated pretreatment samples and less than four
total samples (n¼1), the response rate (GCIG CA125) was reduced
to 56% (95% CI: 44–68%) (41/73), and the difference between
WHO and CA125 response rates only tended to significance
(P¼0.055).
The CA125 criteria had a sensitivity of 100% (95% CI: 74–100%)
(16/16), a specificity of 55% (95% CI: 42–69%) (31/56), a PPV of
39% (95% CI: 24–56%) (16/41) and an NPV of 100% (95% CI: 89–
100%) (31/31) in predicting a CR by the WHO criteria. The CA125
criteria had a sensitivity of 96% (95% CI: 82–100%) (27/28),
a specificity of 68% (95% CI: 52–81%) (30/44), a PPV of
66% (95% CI: 49–80%) (27/41), and an NPV of 97% (95% CI:
83–100%) (30/31) in predicting a response (CRþPR) by the WHO
criteria (Table 3).
In patients assessable by both criteria (n¼72), the two response
criteria were concordant in 79% (95% CI: 68–88%) (57/72) of
patients. Disconcordance in the designation of WHO response and
CA125 response was observed in 21% (95% CI: 12–32%) (15/72) of
patients. The failure of CA125 response criteria to reflect a tumour
shrinkage assessed by WHO criteria was observed in 4% (95% CI:
0.1–18%) (1/28) of the patients. A 50% reduction in the CA125
level despite clinical disease progression (PD) by WHO criteria was
observed in 0% (95% CI: 0.0–31%) (0/10) of patients.
A numeric greater proportion of all patients treated with
second-line treatment (n¼124) are assessable by WHO response
criteria (81%: 100 of 124 patients) than CA125 response criteria
(70%: 87 of 124 patients) (P¼0.076).
CA125 response: ratio criteria
Of 124 patients, 102 patients were evaluable for response by CA125
ratio criteria (CA125X70Uml
 1, one sample), eight patients had
nonevaluable disease (CA125: X35 and o70Uml
 1, one sample)
and 14 patients were described as CA125 normal (CA125
o35Uml
 1). As only one pretreatment CA125 measurement is
required for eligibility by CA125 ratio criteria, the number of
evaluable patients by ratio criteria (n¼102) is numerically higher
than the number of evaluable patients by GCIG CA125 criteria
(n¼87), where two pretreatment measurements are required
(Table 1). Table 3 demonstrates the sequential response rates over
treatment time according to CA125 ratio criteria. The response rate
(CRþPR) after the first cycle of chemotherapy (32%; 95% CI: 23–
42%) was significantly inferior to the response rate after the
second (58%; 95% CI: 47–68%; P¼0.0005), third (63%; 95% CI:
53–73%; Po0.0001) and fourth cycle (64%; 95% CI: 53–74%;
Po0.0001) of treatment. The rate of PD increased numerically with
the number of cycles of second-line therapy from 4% (after one
cycle) to 10% (after four cycles). Of 54 patients (58%) obtaining an
initial biochemical response after two cycles, five patients (9%)
experienced a subsequent progression in CA125 levels after three
or four cycles.
Comparison of WHO and CA125 ratio criteria
Of 124 patients, 84 were assessable both by WHO criteria and by
the CA125 ratio criteria. Table 4 demonstrates the sensitivity,
specificity, PPV, NPV and concordance of the CA125 ratio
response criteria in predicting a tumour response by WHO criteria
(n¼84). Of the four ratio criteria examined, the ratio criteria after
three cycles of chemotherapy were found to provide the highest
Table 2 Correlation between WHO tumour response criteria and the
GCIG CA125 response criteria in second-line treatment of epithelial
ovarian carcinoma (n¼124)
WHO criteria
CA125 criteria CR PR SD PD NM Total
Responders 16 11 14 0 9 50
Nonresponders 0 1 20 10 6 37
NE 7 1 2 7 6 23
Normal
a 41513 1 4
Total 27 14 41 18 24 124
The table depicts the number of patients who fulfilled the criteria. WHO¼World
Health Organization; GCIG¼The Gynaecological Cancer Intergroup;
CA125¼cancer antigen 125; CR¼complete response; PR¼partial response;
SD¼stable disease; NM¼nonmeasurable disease; NE¼nonevaluable disease.
aCA125 normal: CA125 levels below 35Uml
 1.
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95% CI: 64–85%). The reduction in accuracy after the third (75%)
and the fourth (66%) cycle was not statistically significant
(P¼0.27).
DISCUSSION
Several studies have compared CA125 response criteria with the
WHO tumour response criteria in pretreated ovarian carcinoma
patients receiving antineoplastic agents (Davelaar et al, 1996;
Rustin et al, 1997; Bridgewater et al, 1999; Dieras et al, 2002)
(Table 5). Based on data from six different trials, Bridgewater et al
(1999) found a high concordance between CA125 and WHO
response criteria in patients treated with paclitaxel (80%) or
platinum (73%). A high concordance was also found in patients
treated with altretamin (85%) (Rustin et al, 1997) and oxaliplatin
(78%) (Dieras et al, 2002). However, in a large study of Eisenhauer
et al (1994), changes in CA125 levels were not always predictive of
tumour response in paclitaxel treatment of 382 patients. Overall,
49% of patients demonstrated serial decreases in CA125 levels, but
only one-third of these showed a response by standard tumour
measurement criteria. Furthermore, five of 63 patients with
increasing CA125 levels actually had objective tumour responses
by standard criteria rather than disease progression. Unfortu-
nately, the data in that study did not allow a calculation of
concordance between CA125 and WHO response criteria. Simi-
larly, Davelaar et al (1996) found a poor correlation between
CA125 and WHO response criteria (30%), and concluded that
CA125 does not seem to have any predictive value as to tumour
response under paclitaxel treatment. It has been speculated that
paclitaxel interferes with the interpretation of CA125 results
because of increased shedding of CA125 antigen induced by
paclitaxel, but this explanation has not been proved (Pearl et al,
1994). Also, in a study of 5FU-leucovorin in heavily pretreated
patients, the change in CA125 levels failed to correlate with
measured progression in one-third of the patients (Morgan et al,
1995). The results from the different studies have thus been
conflicting, which may partly be explained by the fact that different
CA125 assays and different CA125 cut-off levels have been applied,
in contrast to the present study in which only one CA125 assay was
used (Abbott CA125 EIA), and all serum CA125 analyses were
analysed at the same laboratory (Statens Serum Institute). In a
recent meta-analysis including 14 different drugs in 25 treatment
groups, Rustin et al (2000) found that the CA125 and the WHO
criteria were concordant in 20 of 25 groups, but overall the CA125
response rates were slightly higher than the WHO response rates
by a factor 1.11.
In the present study, the GCIG CA125 response criteria
significantly overestimated a documented decrease in tumour
masses assessed by WHO criteria by 46% (P¼0.045). Alterna-
tively, the WHO response criteria underestimated a CA125
response by a factor 0.68. It is noted that patients with insufficient
samples due to early progression were registered as nonevaluable
(CA125 criteria), and this may represent a potential bias. There-
fore, we performed an intent-to-treat analysis also including one
patient with two elevated pretreatment samples and insufficient
samples to be assessable by GCIG criteria, as suggested by Rustin
(2003). In this analysis, the difference between WHO and GCIG
CA125 response rates only tended to significance (P¼0.055).
There are various reasons to explain the higher response rates of
the CA125 criteria compared with a response by imaging-based
methods such as the WHO (Miller et al, 1981), ECOG (Oken et al,
1982), GOG (Blessing, 1990) or the EORTC (Van Osterum, 1992)
tumour response criteria. Recurrent ovarian carcinoma often
spread to peritoneal surfaces forming multiple small nodules that
may be difficult to assess with conventional imaging techniques
(ultrasonography, CT scans or X-ray). It can be questioned as to
how well the indicator lesions reflect overall tumour load. A
chemotherapy-induced stabilisation of the indicator lesions may
be registered simultaneously with considerable regression of
diffuse carcinosis that is not measurable by WHO tumour response
criteria and therefore not included in the overall evaluation of the
tumour response. Alterations in the CA125 level may thus better
reflect the total tumour load in ovarian carcinoma patients.
The overestimation of response by the GCIG CA125 criteria
could partly be explained by the 14 patients being recorded as
having SD (WHO response: nonresponders) but responding by
CA125, but this patient group does not encompass all cases with
discordant response designation.
Table 3 Sequential response rates according to the CA125 ratio criteria (n¼102)
Ratio after one cycle Ratio after two cycles Ratio after three cycles Ratio after four cycles
CR+PR 32 (23–42) 58 (47–68) 63 (53–73) 64 (53–74)
SD 64 (54–73) 35 (30–46) 28 (19–38) 26 (17–37)
PD 4 (1–10) 6 (2–14) 9 (4–17) 10 (5–19)
Evaluable patients (n) 102 93 90 88
CA125¼cancer antigen 125; CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progressive disease. Numbers in percentage (95% confidence
intervals). CA125 ratio was calculated as the CA125 value after M (M¼1–4) cycles divided by the baseline CA125 value.
Table 4 Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of the CA125 ratio criteria in predicting
tumour response (CR+PR) determined by the WHO criteria (n¼84)
CA125 reduction
Ratio after one cycle Ratio after two cycles Ratio after three cycles Ratio after four cycles
Sensitivity 51 (34–69) 83 (66–93) 91 (77–98) 97 (85–100)
Specificity 84 (70–93) 61 (45–76) 61 (43–76) 63 (46–78)
PPV 69 (48–86) 64 (49–78) 68 (53–81) 71 (56–83)
NPV 71 (57–82) 81 (63–93) 88 (70–98) 96 (80–100)
Accuracy 70 (59–80) 71 (60–81) 75 (64–85) 66 (54–77)
Evaluable patients (n)8 4 7 6 7 3 7 3
CA125¼cancer antigen 125; CR¼complete response; PR¼partial response; WHO¼World Health Organization. Numbers in percentage (95% confidence intervals). CA125
ratio was calculated as the CA125 value after M (M¼1–4) cycles divided by the baseline CA125 value.
CA125 and WHO response in ovarian cancer relapse
B Gronlund et al
380
British Journal of Cancer (2004) 90(2), 377–382 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lIn the present study, a high proportion of patients (83%)
were assessable by WHO tumour response criteria, which may
be due to the fact that all ultrasonographies were performed by
specialists in Radiography. This facility is not available in
all clinics, where assessment may be performed by general
oncologists with considerably less experience. It is speculated
that specialists in imaging methods may be able to detect
tumour progression not detectable by a general oncologist
thus increasing the rate of nonresponders, but this theory
needs to be validated. Objective assessment methods such as the
tumour marker CA125 may reduce the intra- and interobserver
variability in the evaluation of patients with recurrent ovarian
carcinoma.
It is important to rely on accurate response criteria in order to
decide whether or not to continue a second-line chemotherapy that
is considered as palliative. If, theoretically, the CA125 criteria
overestimate a true therapeutic benefit as reflected by a response
by WHO criteria, patients with chemo-resistant disease may
continue an antineoplastic treatment without benefit in terms of
tumour shrinkage, but with the potential risk of developing
chemotherapy-induced toxicity. Similarly, if the WHO response
criteria underestimate a true benefit of an antineoplastic regimen
in terms of a reduction in the number of CA125-expressing cancer
cells as reflected by a CA125 response, a potential active regimen
may be prematurely withdrawn in preference to supportive care. In
this study, none of the patients (0%) experienced a CA125
response despite a clinical disease progression, which means that
none of the patients would have continued treatment despite
tumour progression if CA125 criteria rather than WHO criteria
had been used for guidance of second-line therapy. This finding is
in agreement with other studies finding false-positive results of
declining CA125 levels in very few patients (3%) (Bridgewater et al,
1999). These findings suggest that CA125 might be a more sensitive
indicator of drug activity than WHO criteria. Failure of the CA125
response criteria to reflect a tumour shrinkage assessed by WHO
criteria was observed in one patient, so the risk of discontinuing
treatment on the basis of absence of CA125 response alone is
low. In all, 21% of patients had diverging changes in tumour load
and CA125 level. Patients with tumour shrinkage and a rising
CA125 level may represent progression in resistant tumour clones
as CA125-defined progression frequently antedates clinical pro-
gression by several months. Otherwise, a cancerous mass
expressing high levels of CA125 may respond to treatment while
part of the tumour with low expression of CA125 may exhibit
progression.
Several definitions for CA125 alterations in the monitoring of
ovarian carcinoma treatment have been proposed including single
measurement of CA125 values (Davelaar et al, 1996), relative
percentage reduction in the CA125 level (Eisenhauer et al, 1994;
Rustin et al, 1996, 1997, 2000; Bridgewater et al, 1999; Campos et al,
2001; Meyer et al, 2001; Dieras et al, 2002; Rustin, 2003), CA125
ratio at selected time intervals (Davelaar et al, 1996; de Jong et al,
1997) and exponential regression analysis of the CA125 levels
(Yedema et al, 1993; Pearl et al, 1994; de Jong et al, 1997). The only
definition that has been validated prospectively in different data
sets is the relative percentage response definition described by
Rustin et al (1996). Generally, to be reliable enough for use in
clinical trials, a CA125 response definition needs to take into
account the natural variations in CA125 levels, upper limits of
normal and missing samples. These demands are all met by the
established Rustin CA125 criteria (50 and 75%), which uses
mathematical logics for the systematic analysis of data, using a
computer program (Rustin et al, 1999). However, second-line
treatment of the individual patient with epithelial ovarian
carcinoma represents another clinical setting where the main
focus is palliation. Therefore, the simplicity of the selected CA125
criteria should be in focus in the clinical management of this
patient segment, and accordingly, the simplified GCIG CA125
criteria seem attractive in clinics where computer-aided CA125
analyses are not yet available. Irrespective of the preferred CA125
response algorithm, serial measurement of CA125 is an important
tool in the clinical decision making, especially in patients with ill-
defined tumours.
Using an alternative CA125 response algorithm (CA125 ratio),
the highest accuracy in predicting a tumour response by WHO
criteria was noted after three cycles of chemotherapy (75%). The
accuracy after the fourth cycle (66%) was numerically inferior.
This may be explained by the advent of early third relapses verified
by the finding in 54 patients with initial response after two cycles,
in which five patients (9%) experienced a subsequent progression
in CA125 levels after three or four cycles. Furthermore, the
fluctuation in CA125 levels may have an impact on the comparison
of CA125 ratios after different number of treatment cycles, because
the CA125 ratio response definitions do not require a confirmatory
sample. In summary, in terms of accuracy the ratio criteria added
little compared to the GCIG CA125 response criteria selected in
this study as the main CA125 response algorithm. However, wide
ranges in CIs were noted in all CA125 algorithms.
In conclusion, the GCIG CA125 criteria overestimate a tumour
response measured by WHO criteria in monitoring the efficacy of
topotecan or paclitaxel–carboplatin when used as second-line
regimens in patients with epithelial ovarian carcinoma. Secondly,
the accuracy of CA125-based response criteria in predicting a
tumour response by WHO criteria was not increased by using
CA125 ratio criteria. In patients with diverging changes in
response assessed by imaging-based methods or in tumour marker
levels, other parameters such as improvements in symptoms
should be emphasised to guide treatment. Future studies will
reveal if imaging-based criteria or CA125-based response criteria
best reflect the efficacy of second-line chemotherapy as related to
survival.
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Table 5 Concordance between CA125 and WHO tumour response criteria in pretreated ovarian carcinoma
Author Year No. Treatment Concordance (%)
Davelaar 1996 77 Paclitaxel 30
Rustin 1997 72 Altretamin po 85
Bridgewater 1999 214 Paclitaxel 80
Bridgewater 1999 260 Platinum 73
Dieras 2002 27 Oxaliplatin 78
Gronlund 2004 124 Topotecan or Paclitaxel-Carboplatin 79
CA125¼cancer antigen 125; WHO¼World Health Organization. Concordance means that the designations of response or nonresponse were similar using CA125 and WHO
tumour response criteria.
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